Controlling Shareholder's Stake Updated to 56.6% Following Company Offering
SLGL has more than doubled off its 52-week low of $4.1.
Summary
Moshe Arkin and M. Arkin Dermatology Ltd. updated their beneficial ownership in Sol-Gel Technologies Ltd. to 56.6% following the company's underwritten offering that closed on March 25, 2026.
Key Events · Ownership and Investor Activity · SLGL
-
Updated Beneficial Ownership
Moshe Arkin and M. Arkin Dermatology Ltd. now beneficially own 1,950,113 Ordinary Shares, representing 56.60% of the company's outstanding shares.
-
Post-Offering Update
This amendment reflects the updated holdings following the closing of the Issuer's underwritten offering on March 25, 2026, which increased the total outstanding shares to 3,245,270.
Analysis · SLGL · Life Sciences
This Schedule 13D/A filing updates the beneficial ownership of Moshe Arkin, a controlling shareholder, and his entity M. Arkin Dermatology Ltd. The reported change in percentage ownership (now 56.6%) is a direct result of Sol-Gel Technologies Ltd.'s underwritten offering, which closed on March 25, 2026. While the filing itself does not represent a transaction by the reporting persons, it reflects the dilutive impact of the company's capital raise on existing shareholders, including the controlling stake. Investors should note the updated ownership structure and the context of the company's recent financing activity.
At the time of this filing, SLGL was trading at $79.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $260.3M. The 52-week trading range was $4.10 to $97.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.